Clinical trials: Oligoprogression
Oligoprogressive
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy…
- Trial name
- NCT05846659
- Testing
- IMSA101, Immune checkpoint inhibitor, PULSAR
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- ImmuneSensor Therapeutics Inc.